AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if it is possible to treat your cancer with a new
type of T cell-based immunotherapy (therapy that uses your immune system to treat the
cancer). T cells are a type of white blood cell that helps the body fight infections. This
treatment uses T cells already present within your body that have been modified outside of
the body and returned to target your cancer. This type of treatment is sometimes referred to
as adoptive cell transfer (ACT). In this study the specific type of cells that will be used
is called chimeric antigen receptor T cells (CAR T cells). Another purpose of this study is
to learn about the side effects and toxicities related to this treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Benjamin Tomlinson Case Comprehensive Cancer Center